FROM YAHOO NEWS Latest news, live updates on 2024 election results NasdaqGM - Nasdaq Real Time Price ? USD Verrica Pharmaceuticals Inc. (VRCA) Follow Compare 0.7975 -0.6325 (-44.23%) At close: November 5 at 4:00 PM EST 0.7900 -0.01 (-0.94%) After hours: 7:21 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition – Company reported $0 in product shipments in the third quarter of 2024 and recognized negative net product revenue of $1.9 million, including a provision for product returns of $1.7 million– – Company expects existing distributor inventory to support most demand for dispensed applicator units into the first quarter of 2025 – – Company continues to look for ways to manage expenses and expand access to YCANTH? for the treatment of molluscum contagiosum – – Company announces new senior leadership GlobeNewswire ? yesterday VRCA -44.23% Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference - Posters to highlight the safety data, tolerability data, and antitumor efficacy data of VP-315 for the treatment of basal cell carcinoma as determined by histological clearance - WEST CHESTER, Pa., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the acceptance of two abstracts that will be presented as posters a GlobeNewswire ? 12 days ago VRCA -44.23% Verrica Pharmaceuticals Inc (VRCA) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Rising ... Verrica Pharmaceuticals Inc (VRCA) reports strong YCANTH revenue and strategic advancements, but faces increased losses and market competition. GuruFocus.com ? 27 days ago VRCA -44.23% Verrica Pharmaceuticals Announces Restructuring of Commercial Organization - Company significantly reduces cost structure with a realigned sales, marketing and operational infrastructure - Sales and marketing efforts to focus on pediatricians and expand access beyond dermatologists WEST CHESTER, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced a restructuring of its sales and operati GlobeNewswire ? last month VRCA -44.23% Verrica Pharmaceuticals Inc. (VRCA): Worst 52-Week Low Stock to Buy Now We recently compiled a list of the 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers. In this article, we are going to take a look at where Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) stands against the other Worst 52-Week Low Stocks. The U.S. Federal Reserve conducting a 50 basis point interest rate cut was the […] Insider Monkey ? last month VRCA -44.23% ^GSPC Is Verrica Pharmaceuticals Inc. (VRCA) The Worst 52-Week Low Stocks to Buy Now According to Short Sellers? We recently published a list of 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers. In this article, we are going to take a look at where Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) stands against the other worst 52-week low stocks to buy now according to short sellers. The U.S. Federal Reserve conducting a […] Insider Monkey ? last month VRCA -44.23% ^GSPC Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York WEST CHESTER, Pa., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference in New York City. H.C. Wainwright 26th Annual Global Investment C GlobeNewswire ? 2 months ago VRCA -44.23% When Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Turn A Profit? We feel now is a pretty good time to analyse Verrica Pharmaceuticals Inc.'s ( NASDAQ:VRCA ) business as it appears the... Simply Wall St. ? 2 months ago VRCA -44.23% Verrica stock drops after half patients’ tumours gone in skin cancer trial Data from Verrica’s trial showed that 51% of patients achieved complete histologic clearance, but investors were not happy. Clinical Trials Arena ? 2 months ago VRCA -44.23% GLDAF Why Is Dermatology-Focused Verrica Pharmaceuticals Stock Trading Lower On Wednesday? On Wednesday, dermatology drug developer Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) released preliminary results from Part 2 of its Phase 2 trial of VP-315 for basal cell carcinoma. The Phase 2 trial is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety and tolerability, pharmacokinetics, and efficacy of VP-315 when administered intratumorally to adults with biopsy-proven basal cell carcinoma. The study enrolled 92 adult Benzinga ? 2 months ago VRCA -44.23% Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Tops Revenue Estimates Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of 27.91% and 10.15%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 2 months ago VRCA -44.23% Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results - Reports YCANTH? revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTH’s distribution footprint to include Cencora, Inc. as a specialty distributor – - Announces positive preliminary topline results of Phase 2 clinical study of VP-315 for the treatment of patients with basal cell carcinoma – - Continues to progress preparation for global Phase 3 Common Warts trial with initiation expected in 1H 2025 – - Conference Call Scheduled for Today at 8:30 am ET – WEST CHEST GlobeNewswire ? 2 months ago VRCA -44.23% Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma VP-315 was well tolerated with no reported treatment-related serious adverse events All patients treated with VP-315 had a reduction in tumor size with an overall reduction in tumor size of all lesions treated in Part 2 of approximately 86% Approximately 51% of lesions treated in Part 2 achieved complete histological clearance Patients with residual tumor on average achieved an approximate 71% reduction in tumor size ~3.6 million basal cell carcinomas diagnosed in the U.S. each year, which is ex GlobeNewswire ? 2 months ago VRCA -44.23% Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024 WEST CHESTER, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 14, 2024, to discuss the Company's financial results for the second quarter ended June 30, 2024, and provide an overview of topline results from Part 2 of the GlobeNewswire ? 2 months ago VRCA -44.23% 3 High Insider Ownership US Stocks With Up To 52% Revenue Growth As the U.S. stock market experiences fluctuations with major indices showing minimal changes and investors anticipating rate cuts, it's a critical time to consider the stability and potential growth of companies. High insider ownership can be a strong signal of confidence in a company's future, particularly in such uncertain market conditions. Simply Wall St. ? 3 months ago VRCA -44.23% HSAI CCB 7 Short-Squeeze Stocks That Could Beat Down the Bears Short-squeeze stocks represent one of the boldest forms of contrarianism available. Simply put, it’s a showdown between the bears that are attempting to profit from the downturn of a public enterprise. In their minds, by eliminating weak players from the market, it improves Wall Street’s “gene pool,” if you will. On the other end, the bulls can play the savior role. What makes short-squeeze stocks so compelling, though, is the incentivization profile. On the pessimistic side, speculators make th InvestorPlace ? 3 months ago AIRS KAI TRUP Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains? Zevra Therapeutics (ZVRA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. Zacks ? 3 months ago ZVRA VRCA -44.23% Verrica Pharmaceuticals Settles Cantharidin-Related Lawsuit With Dormer Labs Verrica Pharmaceuticals Settles Cantharidin-Related Lawsuit With Dormer Labs PREMIUM MT Newswires ? 4 months ago VRCA -44.23% Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc. - Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States - YCANTH is the only commercially available, FDA approved therapy for molluscum contagiosum and is clinically proven to be safe and effective WEST CHESTER, Pa., July 01, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the settlement of lit GlobeNewswire ? 4 months ago VRCA -44.23% High Insider Ownership Growth Stocks On US Exchange For June 2024 As the U.S. stock market experiences fluctuations, with recent slips in major indices like the Dow Jones, S&P 500, and Nasdaq from record highs, investors are keenly observing market dynamics and economic indicators such as inflation rates and interest rate expectations. In this context, examining growth companies with high insider ownership might offer valuable insights, as these firms often demonstrate a strong alignment between management's interests and shareholder returns. Simply Wall St. ? 4 months ago VRCA -44.23% HSAI EH Performance Overview Trailing total returns as of 11/5/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return VRCA S&P 500 YTD -89.11% +21.24% 1-Year -80.06% +32.68% 3-Year -93.94% +23.56%
